patent_id,patent_date,patent_title,patent_num_times_cited_by_us_patents,cpc_subclass_ids
12421294,2025-09-23,Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell selection,0,A61K|A61P|C07K|C12N|C12Y
12419954,2025-09-23,Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies,0,A61K|A61P|C07K|C12N
12404509,2025-09-02,Oligonucleotide-based proteolysis targeting chimera,0,A61K|C12N
12391993,2025-08-19,"Methods, treatment, and compositions for characterizing thyroid nodule",0,C12Q
12385920,2025-08-12,IL-6 signaling and breast cancer,0,C12Q|G01N
12385041,2025-08-12,Conditional-siRNAS and uses thereof in treating cardiac hypertrophy,0,C12N|C12Q
12384845,2025-08-12,Activatable masked anti-CTLA4 binding proteins,0,A61K|A61P|C07K
12364724,2025-07-22,Oncolytic virus expressing a car T cell target and uses thereof,0,A61K|A61P|C07K|C12N
12358998,2025-07-15,Anti-CD6 antibody-growth factor complex for treating autoimmune diseases,0,A61K|A61P|C07K
12337032,2025-06-24,Genetically stable recombinant modified vaccinia Ankara (RMVA) vaccines and methods of preparation thereof,0,A61K|A61P|C07K|C12N
12303559,2025-05-20,Multivalent Epstein-Barr virus-like particles and uses thereof,0,A61K|A61P|C07K|C12N
12281152,2025-04-22,TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors,0,A61K|A61P|C07K|C12N
12281151,2025-04-22,CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders,0,A61K|A61P|C07K
12227745,2025-02-18,"Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof",0,A61K|A61P|C12N
12215162,2025-02-04,BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof,0,A61K|A61P|C07K|C12N
12201657,2025-01-21,Adeno-associated virus compositions for restoring HBB gene function and methods of use thereof,0,A01K|A61K|C07K|C12N
12194056,2025-01-14,CCR7 aptamers and uses thereof,0,A61K|A61P|C12N
12178887,2024-12-31,NIR-conjugated tumor-specific antibodies and uses thereof,0,A61B|A61K|C07K
12173000,2024-12-24,Berbamine derivatives and methods of use thereof,0,A61P|C07D
12161714,2024-12-10,Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy,0,A61K|A61P|C07K|C12N
12156911,2024-12-03,Multivalent Kaposi sarcoma-associated herpesvirus-like particles and uses thereof,0,A61K|A61P|C07K|C12N
12150987,2024-11-26,MVA vaccine for delivery of a UL128 complex and preventing CMV infection,0,A61K|A61P|C07K|C12N
12138279,2024-11-12,Bi specific aptamer,0,A61K|A61P|C12N
12129286,2024-10-29,Membrane-bound IL-12 for cellular immunotherapy,0,A61K|A61P|C07K|C12N
12115189,2024-10-15,T cells for expression of chimeric antigen receptors and other receptors,0,A61K|A61P|C07K|C12N
12084687,2024-09-10,Chimeric poxvirus compositions and uses thereof,1,A61K|A61P|C07K|C12N
12060435,2024-08-13,Multi-specific ligand binders,0,A61K|A61P|C07K|C12N
12054736,2024-08-06,Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof,0,A61K|A61P|C07K|C12N
12054711,2024-08-06,Meta-stable oligonucleotides junctions for delivery of therapeutics,0,B82Y|C12N
12054447,2024-08-06,PCNA inhibitors,0,A61K|A61P|C07C|C07D
12043673,2024-07-23,Complementary RNA linked bispecific T-cell engaging antibodies,0,A61K|C07K
12012446,2024-06-18,Epstein-Barr virus antibodies and uses thereof,0,A61K|A61P|C07K
11981885,2024-05-14,"System, device and method for production of bioproduct including high density cell respirator (HDCR) for intensified production of adeno-associated viruses (AAV) and cell-based production",0,C12M|C12N
11981740,2024-05-14,BAFF-R antibodies and uses thereof,0,A61K|A61P|C07K
11980629,2024-05-14,Conditioning regimens and methods for inducing mixed chimerism,0,A01K|A61K|A61P|C07K
11974993,2024-05-07,Solution formulations of CX-011,0,A61K
11974990,2024-05-07,TXNIP-TRX complex inhibitors and methods of using the same,0,A61K|A61P
11965174,2024-04-23,Adeno-associated virus vector variants for high efficiency genome editing and methods thereof,0,A61K|A61P|C07K|C12N
11964984,2024-04-23,TXNIP-TRX complex inhibitors and methods of using the same,0,A61P|C07D
11964006,2024-04-23,Multivalent Epstein-Barr virus-like particles and uses thereof,1,A61K|A61P|C07K|C12N
11939575,2024-03-26,"Modified tracrRNAs gRNAs, and uses thereof",0,A61K|C12N
11926826,2024-03-12,Twist signaling inhibitor compositions and methods of using the same,0,A61K|C12N
11926652,2024-03-12,CTLA4-binding protein peptide-linker masks,0,A61K|C07K
11918606,2024-03-05,CD123-specific chimeric antigen receptor redirected t cells and methods of their use,0,A61K|A61P|C07K|C12N
11912995,2024-02-27,CTLA-4 aptamer conjugates,1,A61K|C12N
11897952,2024-02-13,Mechanically interlocking complexes,0,A61K|C07K
11891619,2024-02-06,Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof,0,A61K|C07K|C12N
11884930,2024-01-30,Method of inactivating a glucocorticoid receptor gene in an isolated cell,0,A61P|C07K|C12N|G01N
11858879,2024-01-02,PARG inhibitors and method of use thereof,0,A61P|C07C
11857633,2024-01-02,Phosphorothioate-conjugated miRNAs and methods of using the same,0,A61K|C12N
11845938,2023-12-19,Aptamer compositions and the use thereof,0,A61K|C12N
11844833,2023-12-19,Expression system for expressing herpesvirus glycoprotein complexes,0,A61K|A61P|C07K|C12N
11835499,2023-12-05,Methods of quantifying methylglyoxal-induced nucleic acid adducts,0,G01N|H01J
11833226,2023-12-05,Recombinant adeno-associated vectors for targeted treatment,0,A61K|C07K|C12N
11801266,2023-10-31,Methods of using anti-MIR126 compounds,1,A61K|A61P|C07K|C12N
11780815,2023-10-10,DNA2 inhibitors for cancer treatment,0,A61K|C07D
11779657,2023-10-10,Compositions and methods for mitochondrial genome editing,0,A61K|C07K|C12N|C12Y
11767530,2023-09-26,Splice inhibiting oligonucleotides,0,C12N
11767529,2023-09-26,"Short hairpin RNA compositions, methods of making and applications thereof",0,C12N
11767351,2023-09-26,Recombinant lectin and uses thereof,0,A61K|C07K|G01N
11766442,2023-09-26,T-cell lymphoma treatments,0,A61K|A61P|C07D
11759530,2023-09-19,TKI permeability enhancers,0,A61K|A61P|C12N
11754567,2023-09-12,Cancer detection and ablation system and method,0,A61B|G01N|G06N|G16H
11744862,2023-09-05,CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis,0,A61K|A61P|C07K|C12N
11730797,2023-08-22,CS1 targeted chimeric antigen receptor-modified T cells,1,A61K|A61P|C07K|C12N
11730789,2023-08-22,Cell penetrating antibodies,0,A61K|A61P|C07K|C12N
11726087,2023-08-15,"Methods, compositions, and kits for detection of aspergillosis",0,A61K|A61P|C07K|C12Q|G01N
11717568,2023-08-08,MVA vaccine for delivery of a UL128 complex and preventing CMV infection,0,A61K|A61P|C07K|C12N
11701405,2023-07-18,Chimeric antigen receptors and methods for reducing toxicity,0,A61K|C07K|C12N
11696959,2023-07-11,Nanoparticle-cell construct with platinum anti-cancer agent,0,A61K|A61P|B82Y
11690908,2023-07-04,Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy,1,A61K|A61P|C07K|C12N
11686725,2023-06-27,Detection and treatment of neurological diseases,0,A61K|C07K|C12N|C12Q|G01N|G16H
11680102,2023-06-20,Anti-BAFF receptor antibodies and uses thereof,0,C07K
11672812,2023-06-13,Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer,0,A61K|A61P
11666672,2023-06-06,Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia,0,A61B|A61K|A61N|C07K
11661463,2023-05-30,Cell penetrating protein-antibody conjugates and methods of use,0,A61K|A61P|C07K|C12N
11646099,2023-05-09,Method for determining lymphoma type and providing treatment,0,C12Q|G16B
11643659,2023-05-09,Conditional-siRNAS and uses thereof in treating acute myeloid leukemia,2,C12N|C12Y
11643655,2023-05-09,Methods for intracellular delivery and enhanced gene targeting,0,A61K|C12N
11618780,2023-04-04,Composition and method for activating latent human immunodeficiency virus (HIV),0,A61K|A61P|C07K
11607457,2023-03-21,Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same,0,A61K|A61P
11604185,2023-03-14,Methods for detection of botulinum neurotoxin,0,C07K|G01N
11602554,2023-03-14,P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof,0,A61K|A61P|C07K|C12N
11597774,2023-03-07,Antibody variable domains and antibody constructs,0,A61K|A61P|C07K
11591596,2023-02-28,"Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof",2,A61K|A61P|C12N
11584760,2023-02-21,Dithio ETP derivatives,0,A61K|A61P|C07D|Y02A
11583509,2023-02-21,Compound for treating cancer and diabetes,0,A61K|C07D
11579051,2023-02-14,Stable dithizone solutions and formulations and methods for their use,0,C07C|G01N
11578079,2023-02-14,SUMO inhibitor compounds and uses thereof,0,A61K|A61P|C07D
11554178,2023-01-17,Compositions and methods of modulating macrophage activity,0,A61K|A61P|C12N
11549941,2023-01-10,Nucleic acid-functionalized nanoparticles,0,G01N
11541121,2023-01-03,Phosphorothioate-conjugated peptides and methods of using the same,0,A61K|A61P
11541114,2023-01-03,Genetically stable recombinant modified vaccinia Ankara (rMVA) vaccines and methods of preparation thereof,0,A61K|A61P|C07K|C12N
11541062,2023-01-03,Methods of treating advanced prostate cancer,0,A61K|A61P
11535847,2022-12-27,Multivalent oligonucleotide assemblies,0,C12N
11505829,2022-11-22,"Methods, treatment, and compositions for characterizing thyroid nodule",0,C12Q
11505523,2022-11-22,HDAC8 inhibitors for treating cancer,0,A61P|C07C|C07D
11466097,2022-10-11,Chimeric antigen receptors targeted to PSCA,0,A61K|A61P|C07H|C07K|C12N
11464865,2022-10-11,"Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof",1,A61K|A61P|C12N
11434504,2022-09-06,Adeno-associated virus vector variants for high efficiency genome editing and methods thereof,0,A61K|A61P|C07K|C12N
11427819,2022-08-30,Coexpression of CAS9 and TREX2 for targeted mutagenesis,0,C12N|C12Y
11413315,2022-08-16,Neural stem cell-mediated cancer treatment,0,A61K|A61P|C07K|C12N
11413286,2022-08-16,Producing astrocytes using small molecules,0,A61K|A61P|C12N
11407998,2022-08-09,Twist signaling inhibitor compositions and methods of using the same,0,A61K|C12N
11401323,2022-08-02,Epstein-Barr virus antibodies and uses thereof,0,A61K|C07K|C12N
11389529,2022-07-19,Expression system for expressing herpesvirus glycoprotein complexes,0,A61K|A61P|C07K|C12N
11389460,2022-07-19,Methods and compositions for treating endometrial cancer,0,A61K|A61P
11384137,2022-07-12,MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof,0,A61K|A61P|C07K|C12N|G01N
11370842,2022-06-28,Anti-IL1RAP antibodies,0,A61P|C07K
11345656,2022-05-31,PCNA inhibitors,1,A61K|A61P|C07C|C07D
11324731,2022-05-10,TXNIP-TRX complex inhibitors and methods of using the same,1,A61K|A61P
11311622,2022-04-26,Development of masked therapeutic antibodies to limit off-target effects,0,A61K|C07K
11311608,2022-04-26,Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency,0,A61K|A61P|C12Y
11306329,2022-04-19,Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof,0,A61K|C07K|C12N
11306072,2022-04-19,5-bromo-indirubins,1,A61K|A61P|C07D
11279752,2022-03-22,Tumor-selective CTLA-4 antagonists,0,A61P|C07K|C12N
11278594,2022-03-22,Chimeric immunoreceptor useful in treating human cancers,0,A61K|A61P|C07H|C07K|C12N
11268152,2022-03-08,Markers of breast cancer and methods for the use thereof,0,A61K|A61P|C12Q
11266618,2022-03-08,Methods of quantifying N2-(1-carboxyethyl)-2′-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG,0,A61K|A61N|A61P|G01N
11261491,2022-03-01,Methods and compositions for measuring beta cell death,0,C12Q
11261449,2022-03-01,Anti-cancer RNA aptamers,0,A61K|C12N
11246942,2022-02-15,Meditopes and meditope-binding antibodies and uses thereof,0,A61K|B82Y|C07K
11242568,2022-02-08,DNA methylation diagnostic test for breast cancer,0,A61P|C12Q
11242531,2022-02-08,Compositions and methods for the treatment of hypercholesterolemia,0,A61K|A61P|C12N
11236341,2022-02-01,RNA aptamers against transferrin receptor (TFR),0,A61K|A61P|C07K|C12N|G01N
11230577,2022-01-25,Chimeric antigen receptors containing a chlorotoxin domain,0,A61K|A61P|C07K|C12N
11225665,2022-01-18,P38 map kinase inhibitors,0,C12N|C12Y
11219635,2022-01-11,Bi-specific aptamer,0,A61K|A61P|C12N
11213510,2022-01-04,Thioindirubins,0,A61K|A61P|C07D
11208654,2021-12-28,Methods and compositions for the treatment of cancer or other diseases,1,A61K|A61P|C07H|C07K|C12N
11198675,2021-12-14,DNA2 inhibitors for cancer treatment,1,A61K|C07D
11197919,2021-12-14,Chimeric antigen receptors targeting HER2,5,A61K|A61P|C07K|C12N
11191745,2021-12-07,Silica nanoparticle with an insoluble drug,0,A61K|A61P|Y10S
11187704,2021-11-30,IL-6 signaling and breast cancer,1,C12Q|G01N
11186840,2021-11-30,CTLA-4 aptamer conjugates,2,A61K|C12N
11186642,2021-11-30,Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies,0,C07K
11180761,2021-11-23,PDGFR RNA aptamers,0,A61K|C12N|G01N
11179361,2021-11-23,Methods of quantifying N2-(1-carboxyethyl)-2′-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG,0,A61K|A61N|A61P|G01N
11167007,2021-11-09,FOXM1 modulators and uses thereof,0,A61K|A61P
11161908,2021-11-02,BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof,0,A61K|A61P|C07K|C12N
11155783,2021-10-26,Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection,3,A61K|A61P|C07K|C12N|C12Y
11141492,2021-10-12,Anticancer combinations,6,A61K|A61P|C12N|C12Y|Y02A
11136405,2021-10-05,BAFF-R antibodies and uses thereof,0,A61K|A61P|C07K
11116834,2021-09-14,Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy,5,A61K|A61P|C07K|C12N
11116777,2021-09-14,Conditioning regimens and methods for inducing mixed chimerism,1,A01K|A61K|A61P|C07K
11104902,2021-08-31,Splice inhibiting oligonucleotides,1,C12N
11058700,2021-07-13,Macrocyclic lactones and uses thereof as modulators of purinergic receptors,0,A61K
11041859,2021-06-22,Methods of identifying SENP1 inhibitors,0,G01N
11015266,2021-05-25,Chemically encoded spatially addressed library screening platforms,1,B82Y|C12N|C40B|G01N
11015265,2021-05-25,Chemically encoded spatially addressed library screening platforms,0,B82Y|C12N|C40B|G01N
11013753,2021-05-25,TLX and MIR-219 as potential therapeutic targets for neurodevelopmental disorders,0,A61K|A61P|C07K|C12N
11007211,2021-05-18,CCR7 aptamers and uses thereof,0,A61K|A61P|C12N
10987428,2021-04-27,Phosphorothioate-conjugated miRNAs and methods of using the same,1,A61K|C12N
10987420,2021-04-27,Synthetic conjugate of CpG DNA and T-help/CTL peptide,0,A61K|C07K|C12N
10980840,2021-04-20,"Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction",0,A61K|C12N|C12Y
10968431,2021-04-06,Adoptive transfer of CD8+ T cell clones derived from central memory cells,1,A61K|C12N
10967070,2021-04-06,Cell penetrating conjugates and methods of use thereof,2,A61K|A61P|C07K|C12N
10961538,2021-03-30,Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy,5,A61K|A61P|C12N|C12Y|Y02A
10946061,2021-03-16,Peptide inhibitors of twist,0,A61K|C07K
10913706,2021-02-09,PCNA inhibitors,2,A61K|A61P|C07C|C07D
10907175,2021-02-02,Isolated human cell with an inactivated glucocorticoid receptor gene,1,A61P|C07K|C12N|G01N
